Sort
82,697 grants matching “vaccine development”
Evolution of drug resistance in Candida glabrata
$708,143Gavin J Sherlock · Stanford University · R01 · FY2019 · AI
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS
$708,106Theodora Hatziioannou · Rockefeller University · R01 · FY2019 · AI
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS
$708,106Theodora Hatziioannou · Rockefeller University · R01 · FY2020 · AI
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS
$708,106Theodora Hatziioannou · Rockefeller University · R01 · FY2021 · AI
EpiModel 2.0: Integrated Network Models for HIV/STI Prevention Science
$708,077Samuel Jenness · Emory University · R01 · FY2020 · AI
Developmental Research Plan
$708,074David H Walker · University Of Texas Med Br Galveston · U54 · FY2010 · AI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
$708,066Ofer Levy · Boston Children'S Hospital · U01 · FY2017 · AI
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
$708,050Harel Dahari · Loyola University Chicago · R01 · FY2023 · AI
Pathogenesis of Tick-Borne Flavivirus Infections
$708,016Marshall Bloom · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Analytic Methods for HIV Treatment and Co-Factor Effects
$708,016James M Robins · Harvard School Of Public Health · R37 · FY2010 · AI
Adjuvant Development Program: Leading to an Opioid Vaccine
$708,000Ofer Levy · Boston Children'S Hospital · N01 · FY2019 · AI
HPV-related Oropharyngeal Cancer Screening and Monitoring through Remote Self-Sampling
$707,991Erich M Sturgis · Baylor College Of Medicine · U01 · FY2024 · DE
Optimization of Small-Molecule Inhibitors of Shiga and Ricin Toxins
$707,990Yuan-Ping Pang · Mayo Clinic Rochester · U01 · FY2010 · AI
Multivalent Tick-Microbe targeted Lyme disease vaccines
$707,956Utpal Pal · Univ Of Maryland, College Park · R01 · FY2020 · AI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model
$707,956Karsten R.o. Hazlett · Albany Medical College · R01 · FY2020 · AI
HIVRAD: Structural approaches to vaccine development
$707,838Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2007 · AI
Neutralizing and non-neutralizing antibody effector functions in HIV infected children
$707,803Genevieve Giny Fouda Amou Ou · Duke University · R01 · FY2021 · AI
The Role Of Innate Immunity Genes In Viral Infection and Disease Progression
$707,803Steven R Kleeberger · National Institute Of Environmental Health Sciences · ZIA · FY2009 · ES
Understanding Innate Immune Recognition and IFN-g-Mediated Immunity in Cryptosporidiosis
$707,782Felix Yarovinsky · University Of Rochester · R01 · FY2024 · AI
Understanding Innate Immune Recognition and IFN-g-Mediated Immunity in Cryptosporidiosis
$707,782Felix Yarovinsky · University Of Rochester · R01 · FY2025 · AI
SERCEB Individual Career Development Support Program
$707,755Philip Frederick Sparling · Univ Of North Carolina Chapel Hill · U54 · FY2012 · AI
Defining the Inflammation and Immunity Transcriptome in Severe Malarial Anemia for Immunotherapeutic Discovery
$707,737Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2021 · AI
Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice
$707,737Jeremy Allen Goettel · Vanderbilt University Medical Center · R01 · FY2024 · AI
Advancement of a Defined, Protective, Live Attenuated Tularemia Vaccine
$707,728Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2014 · AI
B-cell biology scientific research support component
$707,727Garnett H Kelsoe · Duke University · UM1 · FY2012 · AI